Cortisol & Aldosterone

  • Cortisol : H-P Axis์˜ ์˜ํ–ฅ์„ ๋งŽ์ด ๋ฐ›์Œ.
  • Aldosterone : RAAS ์‹œ์Šคํ…œ์— ์˜ํ•ด ์กฐ์ ˆ๋˜๋Š” ๋ถ€๋ถ„์ด ๋” ํผ.
  • ์—๋””์Šจ : ์•Œ๋„์Šคํ…Œ๋ก  ๋ถ„๋น„๋ฅผ ํ•˜์ง€ ๋ชปํ•จ

Hypoadrenocorticism (HOAC), adrenocortical insufficiency

  • Primary hypoadrenocorticism (= Addisonโ€™s disease) : ๋ถ€์‹ ํ”ผ์งˆ ๊ธฐ๋Šฅ ์ž์ฒด์— ๋ฌธ์ œ
    • aldosterone & cortisol ๋‘˜ ๋‹ค ๊ฐ์†Œ
    • ์›์ธ์€ ๋ช…ํ™•ํ•˜๊ฒŒ ๋ฐํ˜€์ง€์ง„ ์•Š์•˜์ง€๋งŒ,
      • immune-mediated destruction
      • neoplasia, tuberculosis, fungal dz
      • granulomatous or infectious
      • trilostane : ํ”ผ์งˆ ๊ดด์‚ฌ ์œ ๋ฐœ X, ํ•ฉ์„ฑ ์ž์ฒด๋งŒ ์–ต์ œ. but ์•„์ฃผ ์†Œ์ˆ˜์˜ ํ™˜์ž์—์„œ๋Š” ๋ถ€์‹  ํ”ผ์งˆ ๊ดด์‚ฌ ์œ ๋ฐœ
      • mitotane :`
  • Secondary hypoadrenocorticism : ๋‡Œํ•˜์ˆ˜์ฒด์˜ ๋ฌธ์ œ๋กœ ACTH๊ฐ€ ๋ถ„๋น„๋˜์ง€ ์•Š์•„ ์ด์ฐจ์ ์œผ๋กœ ๋ถ€์‹  ํ”ผ์งˆ ๊ธฐ๋Šฅ ์ €ํ•˜
    • Aldosterone์€ RAAS ์‹œ์Šคํ…œ์˜ ๊ด€์—ฌ โ†‘ โ†’ ์ •์ƒ ๋ฒ”์œ„ ์œ ์ง€
    • Cortisol๊ณผ ์„ฑํ˜ธ๋ฅด๋ชฌ๋งŒ ์ €ํ•˜๋จ
    • ์›์ธ
      • ์„ ์ฒœ์ ์ธ ๋‡Œ์˜ damage
      • ๋Œ€๋ถ€๋ถ„์€ iatrogenic : ์Šคํ…Œ๋กœ์ด๋“œ์˜ ์žฅ๊ธฐ๊ฐ„ ๋ณต์šฉ
  • Tertiary hypoadrenocorticism
    • ์‹œ์ƒํ•˜๋ถ€์˜ ๋ฌธ์ œ โ†’ CRH๋„ ๊ฐ์†Œํ•˜๋Š” ๊ฒƒ์ด ํŠน์ง•
    • ์‚ฌ๋žŒ์—์„œ๋„ ๋“œ๋ฌผ๊ณ , ๊ฐœ์—์„œ๋Š” ๋ฐœ์ƒ ๋ณด๊ณ ๊ฐ€ ์—†๋‹ค.

Primary hypoadrenocorticism

  • Typical : 2๊ฐ€์ง€ ํ˜ธ๋ฅด๋ชฌ์ด ๋‹ค ๊ฒฐํ•
  • Atypical : cortisol๋งŒ ๊ฒฐํ•๋œ ๋“œ๋ฌธ ๊ฒฝ์šฐ

Clinical features

Predisposition

333

  • Age : young ~ middle-aged
  • Breed : Poodle์—์„œ ํ˜ธ๋ฐœ
  • Sex : ์•”์ปท์—์„œ 2~2.5๋ฐฐ๊นŒ์ง€ ํ˜ธ๋ฐœ
Common clinical features

: ์—„์ฒญ ๋น„ํŠน์ด์ . ์ฆ์ƒ๋งŒ ๋ณด๊ณ  ์˜ˆ์ธกํ•˜๊ธฐ๋Š” ์‰ฝ์ง€ ์•Š์Œ.

  • Lethargy, anorexia, weakness, weight loss, shivering/shaking (์ €ํ˜ˆ๋‹น์œผ๋กœ ์ธํ•œ ์ „์‹  ์ฆ์ƒ)
  • Vomiting, diarrhea, abdominal pain (cortisol์˜ ์œ„์žฅ๊ด€ ํก์ˆ˜ ๊ฐ์†Œ)
  • PUPD (ํ”ํ•˜์ง€ ์•Š์Œ, ์ˆ˜ํ™”๋˜๋ฉด์„œ ๋‚˜ํƒ€๋‚˜๊ธฐ๋„ ํ•จ)

์ŠคํŠธ๋ ˆ์Šค ์ด๋ฒคํŠธ์— ์•…ํ™”๋˜๋Š”์ง€ / ์Šคํ…Œ๋กœ์ด๋“œ๋‚˜ ์ˆ˜์•ก ์ฒ˜์น˜์— ๋ฐ˜์‘์„ฑ์ด ์ข‹์Œ

Addison crisis : ์—๋””์Šจ์œผ๋กœ ์ธํ•œ ์‘๊ธ‰ ์ƒํ™ฉ

  • Addison crisis, acute adrenal insufficiency
  • ํ‰์ƒ 1๋ฒˆ ์ •๋„๋Š” ๊ฒฝํ—˜ํ•  ์ˆ˜ ์žˆ์œผ๋‹ˆ, ๋ณดํ˜ธ์ž์—๊ฒŒ ์‚ฌ์ „ ๊ณ ์ง€ ๋งค์šฐ ์ค‘์š”!! ๋ฐ”๋กœ ๋ณ‘์› ๋ฐ๋ ค์˜ค๋„๋ก.
  • ์ฟ ์‹ฑ/๊ฐ‘๊ธฐ์ €์— ๋น„ํ•ด emergency ๋ฐœ์ƒ ๊ฐ€๋Šฅ์„ฑ โ†‘
  • Coma๋กœ ๋น ๋ฅด๊ฒŒ ์ง„ํ–‰
Clinical features
  • Vomiting, diarrhea
  • ์‹ฌํ•œ GI bleeding
  • ์‹ฌํ•œ ํƒˆ์ˆ˜, collapse ์ƒํƒœ๋‚˜ shock ๋ฐœ์ƒ ๊ฐ€๋Šฅ

Diagnosis

  • ์‹ฌํ•œ ํƒˆ์ˆ˜, ์ €ํ˜ˆ๋Ÿ‰์ฆ ๋•Œ๋ฌธ์— ๋งฅ๋ฐ• ์ €ํ•˜

  • ์ „ํ•ด์งˆ ๋ถˆ๊ท ํ˜•์ด ํ”ํ•˜์ง€๋งŒ, ๋„ˆ๋ฌด ๋น„ํŠน์ด์ 

    • Na:K ratio < 27
    • ํ•˜์ง€๋งŒ ์ด๊ฒƒ๋„ ๋น„ํŠน์ด์ , ๋‚ฎ์„ ์ˆ˜ ์žˆ๋Š” Ddx๊ฐ€ ~~~
  • ์ €ํ˜ˆ๋Ÿ‰์ฆ ์ง€์† โ†’ ์กฐ์ง์œผ๋กœ ๊ฐ€์•ผ ํ•  ํ˜ˆ๋ฅ˜๊ฐ€ ์ถฉ๋ถ„X โ†’ Multi Organ Failure ๋ฐœ์ƒ ๊ฐ€๋Šฅ

  • ํƒˆ์ˆ˜ ๊ต์ •ํ•˜๋ฉด masking๋œ ์†Œ๊ฒฌ ๋‚˜ํƒ€๋‚  ์ˆ˜๋„

  • ์ค‘์ฆ ์ƒํƒœ์—์„œ๋„ stress leukogram ๋‚˜ํƒ€๋‚˜์ง€ ์•Š๋Š” ๊ฒŒ ํŠน์ง•. (Absence of a stress leukogram)

    • WBC ์˜ฌ๋ผ๊ฐˆ ๋•Œ
  • ์š”๋น„์ค‘ ๊ฐ์†Œํ•˜๋Š” ์ด๋Ÿฐ ์งˆํ™˜๋“ค๊ณผ๋„ ์œ ์‚ฌ.

  • ACTH stimulation test : iatrogenic์— ๋Œ€ํ•œ ๊ฐ๋ณ„ ํ•„์š”.

  • ์—๋””์Šจ ์ง„๋‹จ์—์„œ๋Š” IV๋กœ ํ•˜๋Š” ๊ฒŒ ๊ถŒ์žฅ๋œ๋‹ค. ํƒˆ์ˆ˜+์ €ํ˜ˆ๋Ÿ‰์ฆ, ํก์ˆ˜๋„ ๋ถ„ํฌ๋„ ์ž˜ ์•ˆ ๋˜๊ธฐ ๋•Œ๋ฌธ์— ๊ทธ๋‚˜๋งˆ IV๋ฅผ ํ•ด์•ผ ์œ ๋ฆฌ.

  • ๊ฒ€์‚ฌ ๊ฒฐ๊ณผ์— ์˜ํ–ฅ์„ ์ค„ ์ˆ˜ ์žˆ๋Š” factors

    • ๊ฒ€์‚ฌ ์ •ํ™•๋„๋ฅผ ๋†’์ด๊ธฐ ์œ„ํ•ด
  • Baseline endogenous ACTH :

์š”์•ฝ
Baseline Diagnostics
P/EHypovolemia
Hypotension
Dehydration
Weak femoral pulse
Abdominal pain
*Hypovolemic shock (Addison crisis) ํ™•์ธ
Electrolytes์ „ํ•ด์งˆ ๋ถˆ๊ท ํ˜• โ‡’ Na:K ratio <27
ECG๋ณด์ƒ์„ฑ ๋นˆ๋งฅ,
S-chemHypercalcemia, Azotemia,
CBCNon-regenerative anemia (normocytic, normochromic)
Eosinophilia
Lymphocytosis
Reverse stress leukogram
UrinalysisUrine specific gravity โ†“ (1.008 to 1.020)
RadiographsMicrocardia
Small cr. lobar pulmonary artery
Narrow posterior vena cava
Microhepatica

๊ฑฐ๋Œ€์‹๋„์ฆ
Ultrasonography์ขŒ์ธก ๋ถ€์‹  ์œ„์ถ• : thickness < 2.8mm
Basal cortisol measurement
๋ฐฐ์ œ์šฉ (์ง„๋‹จ์šฉX)
ACTH stimulation testpost-ACTH cortisol conc. : <2 ฮผg/dl
(2-4ฮผg/dl : grey zone - ์ผ๋ถ€ secondary, CIRCI)
Baseline endogenous ACTH
1์ฐจ์„ฑ/2์ฐจ์„ฑ ๊ตฌ๋ถ„
[Primary] Cortisol-to-ACTH ratio โ†“
[Secondary] Cortisol-to-ACTH ratio โ†‘
Plasma aldosterone concentrationPost-ATCH aldosterone conc.
Aldosterone-to-renin ratio (ARR)

CIRCI

  • ๋„ˆ๋ฌด ์•„ํŒŒ์„œ ์ฝ”ํ‹ฐ์†”์ด ์ž˜ ์•ˆ ๋‚˜์˜ค๋Š” ์ƒํƒœ
  • ์ดˆ๋ฐ˜์— ๋„ˆ๋ฌด ์•„ํ”Œ ๋•Œ๋Š” ํญ๋ฐœ์ ์œผ๋กœ ์ฆ๊ฐ€ํ•˜๊ฑฐ๋‚˜, ์ค‘์ฆ๋„๊ฐ€ ๋„ˆ๋ฌด ์‹ฌํ•˜๊ฑฐ๋‚˜ ๋งŒ์„ฑ์ ์œผ๋กœ ์•„ํ”„๋ฉด hypocholestolemia?
  • ๋„ˆ๋ฌด ์•„ํ”ˆ ํ™˜์ž๋Š” CIRCI ๋ฐฉ์ง€ํ•˜๊ธฐ ์œ„ํ•ด rapid cortisol ์ค€๋‹ค

Treatment

Acute Treatment (์ผ๋‹จ ์ฒ˜์น˜)Chronic Treatment (์žฅ๊ธฐ์  ๊ด€๋ฆฌ)
(๋ณดํ†ต ๊ธ‰์‚ฌ ์›์ธ์€ hypovolemic shock)
Fluid therapy
Glucocorticoid therapy
Mineralocorticoid therapy
Glucocorticoid therapy
Mineralocorticoid therapy
Acute Treatment

์ €ํ˜ˆ๋Ÿ‰์ฆ ๊ต์ •์ด ๊ฐ€์žฅ ์ค‘์š”!! (๊ธ‰์‚ฌ ๋ฐฉ์ง€)

  • ์‹ฌ์žฅ ํ‰๊ฐ€ (์ฒญ์ง„ ์ •๋„)

  • IV catheterization (ํƒˆ์ˆ˜๊ฐ€ ์‹ฌํ•ด์„œ ์ž˜ ์•ˆ ์žกํž˜)

  • ํ˜ˆ๋‹น ์ฒดํฌ ํ•„์ˆ˜ (์ €ํ˜ˆ๋‹น โ†’ ํ˜ˆ๋‹น ๊ต์ • ํ•„์š”)

  • Fluid choice

    • Crystalloid
    • sodium
Fluid choice
0.9 saline (N/S) *3% ๋Š” ๋„ˆ๋ฌด ๋น ๋ฅธ ๋ณด์ถฉ

Shock-dose : 60ml/kg/24h IV) ์‚ฐ์ฆ, hypokalemia ๊ต์ • ์•ˆ ๋จ ๋„ˆ๋ฌด ์‚ฐ์ฆ ์‹ฌํ•˜๋ฉด bicarbonate CRI

  • ์‹ฌ์žฅ ๋ณดํ˜ธ ๋ชฉ์ (hypokalemia ๊ต์ •X)์œผ๋กœ gluconate

Glucocorticoid therapy
Dexamethasone sodium phosphate
Prednisolone sodium phosphate or succinate
Hydrocortisone sodium succinate

Mineralocorticoid therapy
DOCP (desoxycorticosterone pivalate)25์ผ์— 1๋ฒˆ
Fludrocortisone acetateํ•˜๋ฃจ 1-2๋ฒˆ (์•ฝ๋ฌผ ์šฉ๋Ÿ‰ ์กฐ์ ˆ ์šฉ์ด)
  • ์ˆ˜์•ก๊ณผ ๊ฐ™์ด ํ•˜๋ฉด ์ข€ ๋” ๊ณ ๋ คํ•ด์•ผ ํ•จ
  • DOCP ์ฃผ์ž…ํ•˜๋ฉฐ shock-dose๋กœ saline ๋น ๋ฅด๊ฒŒ ์ฃผ์‚ฌํ•˜๋ฉด ๋ถ€์ž‘์šฉ ๊ฐ€๋Šฅ

์ ๊ฒ€

  • Urine output
  • ์–ด๋А ์ •๋„ ์ˆ˜ํ™” ์ž˜ ๋˜๋ฉด ํ•˜๋ฃจ์ดํ‹€๋งŒ ์ง€๋‚˜๋„ ํ™• ์ข‹์•„์ง€๊ณ ,
Chronic Treatment (Long-term ๊ด€๋ฆฌ)
  • PDS : ์ฒœ์ฒœํžˆ tapering

  • DOCP : ๋“ค์–ด๊ฐ€๋ฉด aldosterone์œผ๋กœ ์ „ํ™˜, mineralocorticoid ๋ณด์ถฉ ํšจ๊ณผ๋งŒ

    • ๋ช‡ ์‹œ๊ฐ„ ๋‚ด๋กœ ์ฆ๊ฐ€, 2์ฃผ์ฏค peak, ํ•œ๋‹ฌ ์ •๋„ ์ง€์†
    • SC๋กœ ์ฃผ์‚ฌ
    • Peak ๋•Œ ์ „ํ•ด์งˆ ๋†๋„, ํ™˜์ž body condition ์ฒดํฌํ•ด์„œ ์šฉ๋Ÿ‰ ์กฐ์ ˆ โ‡’ 25์ผ์งธ์— ๊ฒฐ์ •ํ•ด์„œ ์ฃผ์‚ฌ
    • ๋ถ€์ž‘์šฉ : ์ฒด์ค‘ ์ฆ๊ฐ€, ์–ผ๊ตด ๋ถ€์Œ, ์šธํ˜ˆ์„ฑ ์‹ฌ๋ถ€์ „
    • ์ฒ˜์Œ
  • Fludrocortisone acetate

    • ์ฝ”ํ‹ฐ์†”..
    • Hyponatremia ๊ฐœ์„ 
PDS- ์™„์ „ํžˆ ๋‹จ์•ฝํ•˜๊ธด ์–ด๋ ต๊ณ , ๋งŽ์ด ์ค„์ด๋ฉด EOD ์ •๋„๊นŒ์ง€ ๊ธฐ๋Œ€
- Maintenance dosage : 0.25-0.5mg/kg PO q24h
- ๋Œ€์ฆ ์น˜๋ฃŒ๊ฐ€ ์•„๋‹ˆ๋ผ, ๋ถ€์กฑํ•œ ๊ฒƒ์„ ์ฑ„์›Œ์ฃผ๋Š” ์น˜๋ฃŒ ๋ชฉ์ ์ด๊ธฐ ๋•Œ๋ฌธ์— ํ‰์ƒ ๋ณต์šฉ ํ•„์š”
- ๊ณผํ•˜๊ฒŒ ์˜ค๋ž˜ ๋“ค์–ด๊ฐ€๋ฉด ์˜คํžˆ๋ ค ์ฟ ์‹ฑ ์ฆ์ƒ ๋ฐœ์ƒ
- ์ถฉ๋ถ„ํžˆ ๋ณด์ถฉํ•ด์ฃผ์ง€ ๋ชปํ•˜๋ฉด ์ž„์ƒ ์ฆ์ƒ ๊ฐœ์„ ์ด ์—†์Œ
- surgery, trauma, illness, environmental ๋“ฑ ์ด๋ฒคํŠธ๊ฐ€ ์žˆ์„ ๋•Œ ์Šคํ…Œ๋กœ์ด๋“œ ์š”๊ตฌ๋Ÿ‰์ด ํ™• ์ฆ๊ฐ€ํ•จ
- ๊ต์ฒดํ•ด๋ณธ๋‹ค๋ฉด methylprednisolone, dexamethasone
Fludrocortisone acetate
๋ถ€์ž‘์šฉ
  • Follow-up
  • ์˜ˆํ›„
    • ์ƒ์กด ๊ธฐ๊ฐ„์€ ํ‰๊ท  5๋…„ ์ •๋„
    • 12๋…„๊นŒ์ง€๋„ ์ƒ์กด ๊ฐ€๋Šฅ, crisis ์˜ˆ๋ฐฉ์ด ๊ฐ€์žฅ ์ค‘์š”
    • Lifelongํ•˜๊ฒŒ๋Š” ์ข‹์ง€๋งŒ..
    • ๊ตฌํ†  ํ•œ ๋ฒˆ๋งŒ ํ•ด๋„ ํ˜น์‹œ ๋ชจ๋ฅด๋‹ˆ๊นŒ ์˜ค์„ธ์š”